Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $684.49, giving the company a market capitalization of 71.66B. It carries a P/E multiple of 16.15 and pays a dividend yield of 39.1%.
On 2025-11-12, Regeneron(REGN) stock moved within a range of $672.67 to $690.78. With shares now at $684.49, the stock is trading +1.8% above its intraday low and -0.9% below the session's peak.
Trading activity shows a volume of 1.21M, compared to an average daily volume of 973.84K.
The stock's 52-week range extends from a low of $476.49 to a high of $831.00.
The stock's 52-week range extends from a low of $476.49 to a high of $831.00.
REGN News
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron and keeping the price target at $725.00. Meet Your ETF AI Analyst Discover how TipR...
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron and keeping the price target at $767.00. Meet Your ETF AI Analyst Discover how Ti...
Regeneron (REGN) Pharmaceuticals’ treatment of pulmonary arterial hypertension was granted FDA orphan designation status, according to a post to the agency’s we...
Analyst ratings
72%
of 29 ratingsMore REGN News
Below is Validea's guru fundamental report for REGENERON PHARMACEUTICALS INC (REGN). Of the 22 guru strategies we follow, REGN rates highest using our Value Inv...
Regeneron Pharmaceuticals, Inc.'s ( ) stock showed strength, with investors undeterred by its weak earnings report. We think that shareholders might be missing...
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from two Phase 2 clinical trials evaluating its investigational factor XI antibo...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) reported positive data from the late-stage trial, which assessed Dupixent (dupilumab) for treating allergic fu...
(RTTNews) - Sanofi SA (SNY) on Friday announced that the pivotal LIBERTY-AFRS-AIMS phase 3 study of Dupixent, co-developed with Regeneron Pharmaceuticals Inc. (...
Regeneron Pharmaceuticals recently reported strong third-quarter earnings and engaged in new collaborations, including a license and development agreement with...